Predicting Response to Neoadjuvant Chemotherapy in Women with Locally Advanced Breast Cancer in Kenya: Utility of Ki67

Q4 Medicine
E. Mogere, J. Githaiga, F. Owilla, M. Mungania, D. Ojuka
{"title":"Predicting Response to Neoadjuvant Chemotherapy in Women with Locally Advanced Breast Cancer in Kenya: Utility of Ki67","authors":"E. Mogere, J. Githaiga, F. Owilla, M. Mungania, D. Ojuka","doi":"10.4314/AAS.V18I1.5","DOIUrl":null,"url":null,"abstract":"Background: Ki67 levels have been shown to have good predictive value in breast cancer treatment. There is paucity of data on Ki67 levels in predicting response to neoadjuvant chemotherapy (NACT) in Kenya. This study evaluated the utility of Ki67 in predicting response to NACT. Methods: This was a prospective observational study carried out at Kenyatta National Hospital between December 2017 and January 2019 onpatients with locally advanced breast cancer. We recruited 61 women through consecutive sampling technique. Data collected included patient demographics, pre-treatment tumor size, Ki67 levels and tumor biology. After 3 cycles of first-line chemotherapy, ultrasonography was used to determine response. Data were analyzed by SPSS for proportion of change in tumor size. The response was correlated with tumor biology and pretreatment levels of Ki67 using chisquare at a 95% confidence interval. A p-value <0.05 was considered statistically significant. Results: The response rate after 3 cycles of NACT was 39.4%, sensitivity and specificity of Ki67 levels were 70.8% and 43.2% respectively with a cut-off value of 32.5%. Conclusions: Ki67 was found to predict response in our context at a rate of 39.4% at 20% cutoff after 3 cycles. Keywords: Ki67, Breast cancer, Neoadjuvant chemotherapy","PeriodicalId":37442,"journal":{"name":"Annals of African Surgery","volume":"47 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of African Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4314/AAS.V18I1.5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Ki67 levels have been shown to have good predictive value in breast cancer treatment. There is paucity of data on Ki67 levels in predicting response to neoadjuvant chemotherapy (NACT) in Kenya. This study evaluated the utility of Ki67 in predicting response to NACT. Methods: This was a prospective observational study carried out at Kenyatta National Hospital between December 2017 and January 2019 onpatients with locally advanced breast cancer. We recruited 61 women through consecutive sampling technique. Data collected included patient demographics, pre-treatment tumor size, Ki67 levels and tumor biology. After 3 cycles of first-line chemotherapy, ultrasonography was used to determine response. Data were analyzed by SPSS for proportion of change in tumor size. The response was correlated with tumor biology and pretreatment levels of Ki67 using chisquare at a 95% confidence interval. A p-value <0.05 was considered statistically significant. Results: The response rate after 3 cycles of NACT was 39.4%, sensitivity and specificity of Ki67 levels were 70.8% and 43.2% respectively with a cut-off value of 32.5%. Conclusions: Ki67 was found to predict response in our context at a rate of 39.4% at 20% cutoff after 3 cycles. Keywords: Ki67, Breast cancer, Neoadjuvant chemotherapy
预测肯尼亚局部晚期乳腺癌妇女对新辅助化疗的反应:Ki67的效用
背景:Ki67水平已被证明在乳腺癌治疗中具有良好的预测价值。肯尼亚缺乏Ki67水平预测对新辅助化疗(NACT)反应的数据。本研究评估了Ki67在预测NACT疗效方面的效用。方法:这是一项前瞻性观察性研究,于2017年12月至2019年1月在肯雅塔国家医院对局部晚期乳腺癌患者进行了研究。通过连续抽样的方法,我们招募了61名女性。收集的数据包括患者人口统计学、治疗前肿瘤大小、Ki67水平和肿瘤生物学。一线化疗3个周期后,超声检查疗效。数据采用SPSS统计软件分析肿瘤大小变化比例。该反应与肿瘤生物学和Ki67预处理水平在95%置信区间内相关。p值<0.05认为有统计学意义。结果:NACT治疗3个周期后的有效率为39.4%,Ki67水平的敏感性为70.8%,特异性为43.2%,临界值为32.5%。结论:在我们的研究中,Ki67在3个周期后的20%截止率下预测应答率为39.4%。关键词:Ki67,乳腺癌,新辅助化疗
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of African Surgery
Annals of African Surgery Medicine-Surgery
CiteScore
0.50
自引率
0.00%
发文量
48
审稿时长
20 weeks
期刊介绍: The Annals of African Surgery ANN. AFR. SURG. (ISSN: 1999-9674 [print], ISSN: 2523-0816 [online]) is a bi-annual publication that aims to provide a medium for the exchange of current information between surgeons in the African region. The journal embraces surgery in all its aspects: basic science, clinical research, experimental research, and surgical education. The Annals of African Surgery will help surgeons in the region keep abreast of developing surgical innovations. This Ethics Policies document is intended to inform the public and all persons affiliated with The Annals of African Surgery of its general ethics policies. Types of articles published: -Original articles -Case reports -Case series -Reviews -Short communications -Letters to the editor -Commentaries Annals of African Surgery publishes manuscripts in the following fields: - Cardiac and thoracic surgery - General surgery - Neurosurgery - Oral and maxillofacial surgery - Trauma and orthopaedic surgery - Otolaryngology (ear, nose and throat surgery) - Paediatric surgery - Plastic and reconstructive surgery - Urology surgery - Gynaecologic surgery - Surgical education -Medical education -Global surgery - Health advocacy - Innovations in surgery - Basic sciences - Anatomical sciences - Genetic and molecular studies
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信